How a helper protein raises testosterone and changes how drugs are broken down
Activation of androgen biosynthesis and drug metabolism by cytochrome b5
Trying to block a small protein called cytochrome b5 from helping an enzyme that makes testosterone, aiming to lower testosterone for people with androgen-driven conditions like prostate cancer without causing steroid-related side effects.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project ID | NIH-11128009 on NIH RePORTER |
What this research studies
Researchers are studying how cytochrome b5 binds to the enzyme P450 17A1 and boosts the step that makes testosterone. They will use biochemical and biophysical lab methods, plus cell and animal experiments, to map the interaction and test ways to disrupt it. The goal is to find approaches that stop only the testosterone-making reaction (17,20-lyase) while leaving other steroid and drug-processing activities intact. If successful, those findings could guide development of safer medicines for people with androgen-dependent diseases.
Who could benefit from this research
Good fit: People with androgen-driven conditions, such as advanced prostate cancer or disorders of androgen excess, would be the likely future candidates for treatments developed from this work.
Not a fit: Patients whose conditions are not driven by androgens or who need treatments unrelated to steroid biosynthesis are unlikely to benefit from this line of research.
Why it matters
Potential benefit: Could lead to new treatments that lower testosterone effectively for prostate cancer or androgen excess while avoiding the mineralocorticoid side effects that require added steroids.
How similar studies have performed: Existing drugs that block P450 17A1 (for example abiraterone) lower testosterone but cause side effects, and targeting the cytochrome b5–P450 interaction is a newer, mostly preclinical approach.
Where this research is happening
Ann Arbor, United States
- University of Michigan at Ann Arbor — Ann Arbor, United States (Active)
Researchers
- Principal investigator: Auchus, Richard J. — University of Michigan at Ann Arbor
- Study coordinator: Auchus, Richard J.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.